share_log

Scinai Immunotherapeutics Announces The Establishment Of A U.S.-Based Subsidiary For Its Contract Development And Manufacturing Services

Scinai Immunotherapeutics Announces The Establishment Of A U.S.-Based Subsidiary For Its Contract Development And Manufacturing Services

Scinai免疫治疗公司宣布在美国建立一家子公司,以提供其合同开发和制造服务。
Benzinga ·  12/16 22:26

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today the establishment of a U.S.-based subsidiary for its Contract Development and Manufacturing Services. The new subsidiary, incorporated in Delaware, will operate under the name Scinai Bioservices Inc.

Scinai免疫治疗有限公司(纳斯达克:SCNI)(“Scinai”或“公司”)是一家专注于开发炎症和免疫学(I&I)生物产品以及通过其Scinai Bioservices业务部门提供CDMO服务的生物制药公司,今天宣布在美国建立一家子公司,提供合同开发和制造服务。这家新子公司注册在特拉华州,将以Scinai Bioservices Inc.的名义运营。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发